… Diabetic kidney disease (DKD) is one of the most common chronic kidney diseases globally,
with growing incidence and prevalence (1), as 30% to 40% of patients with diabetes will …

… disease (CAD), heart failure (HF), stroke, other cardiovascular (CV) diseases, and diabetic
kidney disease. … fibrillation (AF) as well as kidney disease in part through its influence on the …

… : Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease (…
This pre-specified analysis assessed the effect of dapagliflozin on the rate of change in …

… long-term effects of dapagliflozin on urinary … kidney disease (CKD) and increased albuminuria
(≥3.4 mg/mmol). Patients were randomised to dapagliflozin 10 mg (n = 56), dapagliflozin …

… that they have heart and kidney protective effects in chronic kidney disease (CKD) patients
… the Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin …

… aimed to investigate the effect of dapagliflozin in preventing post-contrast acute kidney
injury (PC-AKI) in patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD) who …

… , and kidney outcomes, and have a consistent benefits for CV death/HHF and progression
of kidney disease with dapagliflozin. … pattern of incremental risk observed with dapagliflozin. …

… We report five cases in which the SLGT2 inhibitor dapagliflozin … dapagliflozin for weight
reduction and glycemic control was worthwhile. We started dosing with 10 mg of dapagliflozin, …

… To explore the underlying mechanisms of ferroptosis-ameliorating effects of dapagliflozin
in diabetic kidney, kidney cortical tissues of mice were isolated for metabolomic analysis (…

… of six to 12 weeks of treatment with SGLT2 inhibitor dapagliflozin compared to placebo on
… albuminuric kidney disease. In addition, we aimed to characterize the effects of dapagliflozin …